ClinicalTrials.gg
CompletedNCT04874948Updated Dec 31, 2024Results posted

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

A Phase 1 interventional study of 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 in Tuberculosis, Tuberculosis, Pulmonary and Bacterial Infections Respiratory, sponsored by Michael Hoelscher. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-31.

Primary conditionTuberculosis, PulmonaryRegistry: TuberculosisReclassifiedWhy we changed it
Registry
Tuberculosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tuberculosis, Pulmonary
Why
  1. The study's listed conditions name Tuberculosis, Pulmonary, a narrower term within Tuberculosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Michael Hoelscher · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study is a Phase 1, single-center, open-label study to investigate the absorption, metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 in 4 healthy adult male subjects

Read the detailed description

A total of 4 evaluable subjects completing all procedures are required. Six (6) subjects will be enrolled in the cohort in order to have 4 evaluable subjects.

The study will consist of a screening period (Day -21 to -2), a baseline period (Day -1), a single dose treatment on Day 1 with a minimum of 96 hours (=4 days) post dose in-house observation period (Days -1 up to afternoon Day 5), and a follow-up visit 30 days (±2 days) after the [14C]BTZ-043 dose.

Subjects will be administered a single 500 mg [14C]BTZ-043 dose as drinking suspension. Subjects will be confined to the clinical site for at least 96 hours following drug administration (ie, afternoon of Day 5). During this time, blood, feces, and urine samples for measurement of [14C]BTZ-043 and metabolites will be collected.

The subjects will be released from the clinic approximately 96 hours to 168 hours after dose administration and upon satisfactory recovery of radioactivity (at least 90%) approved by the Sponsor's scientific advisor after consulation of the Sponsor.

02

Conditions studied

  • Tuberculosis
  • Tuberculosis, Pulmonary
  • Bacterial Infections Respiratory
  • Lung Diseases
  • Mycobacterium Infections

Browse trials for

Keywords

  • Anti-Bacterial Agents
03

In context

Tuberculosis, Pulmonary Reclassified

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

This study's enrollment of 4 is below the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.

Browse Tuberculosis, Pulmonary studies →

Lead sponsor

Michael Hoelscher is the lead sponsor of 19 studies on the registry; 4 are open to participants now.

Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sex : male
  2. Age : 18 years to 55 years, inclusive, at screening.
  3. (BMI) : 18.0 to 29.0 kg/m2, inclusive, at screening.
  4. Weight : 55 to 90 kg, inclusive, at screening.
  5. Status : healthy subjects.
  6. Male subjects, if not surgically sterilized, must agree to use adequate and not donate sperm from admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner, if she is of ) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence, in accordance with the lifestyle of the subject, is also acceptable.
  7. All prescribed medication must have been stopped at least 30 days prior to admission to the clinical research center.
  8. All over-the-counter medications, vitamin preparations (especially vitamin C), other food supplements, and herbal medications (eg, St. John's wort) must have been stopped at least 14 days prior to admission to the clinical research center. An exception is made for paracetamol, which is allowed up to 48 hours prior to study drug administration.
  9. No vaccination within 14 days prior to study drug administration.
  10. Ability and willingness to abstain from alcohol from 48 hours (2 days) prior to screening and admission to the clinical research center.
  11. Ability and willingness to abstain from methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, and energy drinks), grapefruit (juice), corn (whole corn kernels and popcorn), cruciferous vegetables, and bitter oranges from 48 hours (2 days) prior to admission to the clinical research center.
  12. Good physical and mental health on the basis of medical history, physical examination, clinical laboratory, , and vital signs, as judged by the Investigator.
  13. Willing and able to sign the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another study with a radiation burden of >0.1 mSv and ≤1 mSv in the period of 1 year prior to screening; a radiation burden of >1.1 mSv and ≤2 mSv in the period of 2 years prior to screening; a radiation burden of >2.1 mSv and ≤3 mSv in the period of 3 years prior to screening, etc.
  2. Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton [excluding spinal column]), or during work within 1 year prior to drug administration.
  3. Irregular defecation pattern (less than once per day on average).
  4. Employee of PRA, Nuvisan, or the Sponsor.
  5. History of relevant drug and/or food allergies.
  6. Using tobacco products within 60 days prior to drug administration.
  7. History of alcohol abuse or drug addiction (including soft drugs like cannabis products).
  8. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, gamma-hydroxybutyric acid, tricyclic antidepressants, and alcohol) at screening or admission to the clinical research center.
  9. Average intake of more than 24 grams of alcohol per day.
  10. Positive screen for surface antigen (HBsAg), virus (HCV) antibodies, or 1 and 2 antibodies.
  11. Participation in a drug study within 30 days prior to drug administration in the current study. Participation in more than 4 drug studies in the 12 months prior to drug administration in the current study.
  12. Donation or loss of more than 450 mL of blood within 60 days prior to drug administration. Donation or loss of more than 1.5 liters of blood in the 10 months prior to drug administration in the current study.
  13. Significant and/or acute illness within 5 days prior to drug administration that may impact safety assessments, in the opinion of the Investigator.
  14. Unwillingness to consume the Food and Drug Administration (FDA)-recommended high-fat breakfast.
  15. Unsuitable veins for infusion or blood sampling.
  16. Positive nasopharyngeal PCR test for SARS-CoV-2 on Day -1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Single oral administration of 500 mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043

    4 subjects to receive a single oral administration of 14C-labeled radioactive 500mg BTZ-043

    Drug: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043

Interventions

  • Drug500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043

    Single oral administration of 14C-labeled radioactive 500mg BTZ-043

06

What researchers measure

Primary outcomes

  1. Rates and Routes of Excretion

    To determine the rates and routes of excretion of \[14C\]BTZ-043-related radioactivity, including mass balance of total drug-related radioactivity in urine and feces (and vomit, if applicable), following the oral administration of a single 500 mg dose of \[14C\]BTZ-043 in healthy male volunteers. All excreta were collected for the analysis for 14C quick or normal counts of total radioactivity (as feasible). the radioactivity measured was translated into mg eq (Radioactivity equivalent to 1 mg BTZ-043).

    Time frame: Urine and faeces were collected from the administration of the study medication until cumulative excretion reached 90% of total radioactivity administered. This was achieved by all subjects after 168 hours.

  2. Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax)

    To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

    Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing

  3. Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t)

    To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

    Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing

  4. Pharmacokinetics of Total Radioactivity in Blood (T1/2)

    To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

    Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing

  5. Pharmacokinetics of Total Radioactivity in Plasma (T1/2)

    To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

    Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing

  6. Plasma PK of BTZ-043 and Main Metabolites (Cmax)

    To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites.Pharmacokinetic parameters are calculated from the individual plasma level measurements.

    Time frame: Day 1 to Day 3

  7. Plasma PK of BTZ-043 and Main Metabolites (AUC-last)

    To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.

    Time frame: Day 1 to Day 3

  8. Plasma PK of BTZ-043 and Main Metabolites (t1/2)

    To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.

    Time frame: Day 1 to Day 3

  9. Urine Concentrations of BTZ-043 and Main Metabolites

    Urine volume was measured after every micturation and hamilton pools have been prepared for analysis of BTZ-043 and main metabolites by LC-MS. BTZ-043 could only be measured in urine within the first 24h, then no additional BTZ-043 was excreted in urine anymore. The same applies for M1. M2, M4 total and M10 total excretion could be measured in urine up to 48h post dose.

    Time frame: Assessed from time of dosing up to 168 h post dose. BTZ-043 and metabolites were excreted fom 0 - 24 h (BTZ-043 and M1) and from 0 - 48 h (M2, M4 total and M10 total).

Secondary outcomes

  1. Number of Adverse Events

    To assess the safety and tolerability of a single 500 mg oral dose of BTZ-043 administered to healthy volunteers.

    Time frame: Day -1 to day 32

07

Results

Posted Dec 5, 2024

Participant flow

Screening started on 27th September 2021. The first participant was enrolled on October 8th, 2021. The healthy volunteers were recruited by PRA Health Sciences - Early Development Services in 9728 NZ Groningen

Participant flow — Overall Study
MilestoneSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Started4
Completed4
Not completed0

Outcome measures

PrimaryRates and Routes of Excretion

To determine the rates and routes of excretion of \[14C\]BTZ-043-related radioactivity, including mass balance of total drug-related radioactivity in urine and feces (and vomit, if applicable), following the oral administration of a single 500 mg dose of \[14C\]BTZ-043 in healthy male volunteers. All excreta were collected for the analysis for 14C quick or normal counts of total radioactivity (as feasible). the radioactivity measured was translated into mg eq (Radioactivity equivalent to 1 mg BTZ-043).

Time frame:
Urine and faeces were collected from the administration of the study medication until cumulative excretion reached 90% of total radioactivity administered. This was achieved by all subjects after 168 hours.
Reported as:
Mean · mg eq
Rates and Routes of Excretion
mg eqSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
total drug-related radioactivity in urine331 ± 23.2
total drug-related radioactivity in faeces162 ± 23.0
PrimaryPharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax)

To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

Time frame:
Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Reported as:
Mean · ng eq/mL
Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax)
ng eq/mLSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Cmax Plasma8730 ± 2550
Cmax Blood4970 ± 1370
PrimaryPharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t)

To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

Time frame:
Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Reported as:
Mean · h*ng eq/mL
Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t)
h*ng eq/mLSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
AUC-t Plasma125000 ± 26900
AUC-t Blood76700 ± 18500
PrimaryPharmacokinetics of Total Radioactivity in Blood (T1/2)

To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

Time frame:
Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Reported as:
Mean · h
Pharmacokinetics of Total Radioactivity in Blood (T1/2)
hSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Pharmacokinetics of Total Radioactivity in Blood (T1/2)158 ± 24.7
PrimaryPharmacokinetics of Total Radioactivity in Plasma (T1/2)

To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.

Time frame:
Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Reported as:
Mean · h
Pharmacokinetics of Total Radioactivity in Plasma (T1/2)
hSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Pharmacokinetics of Total Radioactivity in Plasma (T1/2)186 ± 18.9
PrimaryPlasma PK of BTZ-043 and Main Metabolites (Cmax)

To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites.Pharmacokinetic parameters are calculated from the individual plasma level measurements.

Time frame:
Day 1 to Day 3
Reported as:
Mean · ng/mL
Plasma PK of BTZ-043 and Main Metabolites (Cmax)
ng/mLSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Cmax BTZ-0431600 ± 509
Cmax M1163 ± 27.5
Cmax M25180 ± 1310
Cmax M4total1190 ± 455
Cmax M1030.6 ± 6.50
PrimaryPlasma PK of BTZ-043 and Main Metabolites (AUC-last)

To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.

Time frame:
Day 1 to Day 3
Reported as:
Mean · h*ng/mL
Plasma PK of BTZ-043 and Main Metabolites (AUC-last)
h*ng/mLSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
AUClast BTZ-0433920 ± 842
AUClast M12710 ± 433
AUClast M241000 ± 6220
AUClast M4total10300 ± 3990
AUClast M10505 ± 199
PrimaryPlasma PK of BTZ-043 and Main Metabolites (t1/2)

To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.

Time frame:
Day 1 to Day 3
Reported as:
Mean · h
Plasma PK of BTZ-043 and Main Metabolites (t1/2)
hSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
T1/2 BTZ-0432.43 ± 1.01
T1/2 M18.65 ± 0
T1/2 M24.90 ± 0.591
T1/2 M4total3.83 ± 0.281
T1/2 M1018.9 ± 10.2
PrimaryUrine Concentrations of BTZ-043 and Main Metabolites

Urine volume was measured after every micturation and hamilton pools have been prepared for analysis of BTZ-043 and main metabolites by LC-MS. BTZ-043 could only be measured in urine within the first 24h, then no additional BTZ-043 was excreted in urine anymore. The same applies for M1. M2, M4 total and M10 total excretion could be measured in urine up to 48h post dose.

Time frame:
Assessed from time of dosing up to 168 h post dose. BTZ-043 and metabolites were excreted fom 0 - 24 h (BTZ-043 and M1) and from 0 - 48 h (M2, M4 total and M10 total).
Reported as:
Mean · mg eq
Urine Concentrations of BTZ-043 and Main Metabolites
mg eqSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
BTZ-043 (M0) Cumulative Amount Excreted 0 - 24h8.83 ± 4.51
M1 Cumulative Amount Excreted 0 - 24h1.53 ± 0.518
M2 Cumulative Amount Excreted 0 - 24h53.9 ± 17.1
M2 Cumulative Amount Excreted 0 - 48h54.7 ± 17.3
M4 total Cumulative Amount Excreted 0 - 24h59.4 ± 9.77
M4 total Cumulative Amount Excreted 0 - 48h60.5 ± 10.2
M10 total Cumulative Amount Excreted 0 - 24h2.47 ± 1.33
M10 total Cumulative Amount Excreted 0 - 48h2.65 ± 1.45
Sum(M0, M1, M2, M4total, M10) Cumulative Amount Excreted 0-24h126 ± 15.7
Sum(M0, M1, M2, M4total, M10) Cumulative Amount Excreted 0-48h128 ± 16.4
SecondaryNumber of Adverse Events

To assess the safety and tolerability of a single 500 mg oral dose of BTZ-043 administered to healthy volunteers.

Time frame:
Day -1 to day 32
Reported as:
Number · Adverse Events
Number of Adverse Events
Adverse EventsSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Number of Adverse Events6

Adverse events

Collected over Day -1 (admission) until follow-up on day 31 or 32. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-0430/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Most frequent other events
EventSingle Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
DizzinessNervous system disorders4/4
SomnolenceNervous system disorders1/4
Oral HerpesInfections and infestations1/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
<=18 years0
Between 18 and 65 years4
>=65 years0
Age, Continuous
Age, Continuous(years)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Mean22 ± 3
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Male4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Race — White3
Race — White + Black or African American1
Region of Enrollment
Region of Enrollment(participants)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Netherlands4
BMI
BMI(kg/m²)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Mean24.3 ± 4.0
Height
Height(cm)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Mean177 ± 2
Weight
Weight(kg)Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043
Mean75.7 ± 13.0
08

Study locations

1 site
  • PRA Health Sciences (PRA) - Early Development Services (EDS)
    Groningen, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2021, 0 months.

Results were first posted in Dec 2024, 3 years 1 month after primary completion.

Of 13 phase 1 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2021
First posted
May 6, 2021
StartActual
Oct 8, 2021
Primary completionActual
Oct 15, 2021
CompletionActual
Nov 9, 2021
Results first posted
Dec 5, 2024
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04874948
Lead sponsor
Michael Hoelscher
Collaborators
Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute
Responsible party
Michael Hoelscher (Director, Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
May 6, 2021
Start date
Oct 8, 2021
Primary completion
Oct 15, 2021
Completion
Nov 9, 2021
Results posted
Dec 5, 2024
Last update
Dec 31, 2024

Study contacts

Jan Jaap van Lier, MD
principal investigator · PRA Health Sciences (PRA) - Early Development Services (EDS)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion